Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2026)

Indivior Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 89000000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 85.42% year-over-year to 89000000.0 in Q1 2026; TTM through Mar 2026 was 251000000.0, a 3685.71% increase from a year earlier, with the FY2025 full-year figure at 210000000.0, up 2900.0% from the prior year.
• Income from Continuing Operations declined to 89000000.0 in Q1 2026 per INDV's latest filing, from 102000000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 102000000.0 in Q4 2025 and bottomed at 98000000.0 in Q2 2024.
• The 3-year median for Income from Continuing Operations is 42000000.0 (2025), against an average of 34000000.0.
• Biggest YoY gain for Income from Continuing Operations was 385.71% in 2025; the steepest drop was 22.58% in 2025.
• Year by year, Income from Continuing Operations stood at 21000000.0 in 2024, then soared by 385.71% to 102000000.0 in 2025, then slipped by 12.75% to 89000000.0 in 2026.
• Per Business Quant, the three latest INDV Income from Continuing Operations figures stand at 89000000.0 (Q1 2026), 102000000.0 (Q4 2025), and 42000000.0 (Q3 2025).